Sanjay Marasini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sanjay Marasini has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer P. Craig
Department of Ophthalmology, Aotearoa New Zealand National Eye Centre, The University of Auckland, New Zealand; Centre for Ocular Research and Education (CORE), School of Optometry and Vision Science, University of Waterloo, Canada; School of Optometry, Aston University, Birmingham, United Kingdom
9 shared publications - Simon J. Dean
Department of Ophthalmology, Aotearoa New Zealand National Eye Centre, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
4 shared publications - Simon Swift
Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
4 shared publications - Ranjana Sharma
Department of Ophthalmology, Dhulikhel Hospital, Kathmandu University, Dhulikhel, Nepal
3 shared publications B P Nepal
Department of Ophthalmology, Kathmandu University Hospital, Dhulikhel
2 shared publicationsBhagvat Prasad Nepal
Department of Ophthalmology, Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Nepal
2 shared publications
Latest Publications
- Open Access
Investigating the Effects of UVC Exposure at the Limbus
Purpose: Preclinical studies report low-intensity ultraviolet C (UVC) light to be safe and effective in treating murine bacterial keratitis, however, limbal impacts of UVC have yet to be investigated directly. This study evaluated the depth and density of UVC-induced DNA damage in the porcine and human limbus following UVC exposures of varying supratherapeutic dose. Methods: The corneoscleral junction (limbus) of full-thickness porcine corneas was exposed to supratherapeutic doses of UVC light (265 nm, 1.93 mW/cm2) for 5, 10, 15, 30, or 60 min (exposure groups) or remained unexposed for the same durations (control groups), with a sample size of 6 per group. In parallel, human corneal tissue was exposed to UVC for 1 or 5 min and processed identically. Following exposure, all tissues were frozen, dissected, and analysed using immunohistochemistry to detect cyclobutane pyrimidine dimers (CPDs) as markers of DNA damage. CPD distribution, depth, and density were subsequently evaluated. Results: CPDs were localised predominantly in the superficial corneal epithelial layers, irrespective of the UVC dose. The mean ± SD thickness of the corneal epithelium in the UVC-exposed groups was 38.9 ± 18.9 µm, and the average depth of CPD formation was 13.3 ± 8.43 µm. The proportions of cells affected by CPDs within the corneal epithelium (mean ± SD) were 47.8 ± 25.6%, 58.5 ± 16.2%, 39.9 ± 26.4%, 41.3 ± 27.3%, and 38.9 ± 28.3% for exposure durations of 5, 10, 15, 30, and 60 min, respectively (p > 0.05). Human cornea showed similarly limited penetration, with no difference in CPD proportions between the 1 and 5 min UVC exposures (p = 0.70). Conclusions: UVC-induced DNA damage in both species was confined to the superficial cellular layers of the cornea, with no detectable damage observed in deeper tissues, including those where limbal stem cells reside, even after supratherapeutic doses of up to one hour of exposure.
Open AccessInvestigating the Effects of UVC Exposure at the Limbus
Purpose: Preclinical studies report low-intensity ultraviolet C (UVC) light to be safe and effective in treating murine bacterial keratitis, however, limbal impacts of UVC have yet to be investigated directly. This study evaluated the depth and density of UVC-induced DNA damage in the porcine and human limbus following UVC exposures of varying supratherapeutic dose. Methods: The corneoscleral junction (limbus) of full-thickness porcine corneas was exposed to supratherapeutic doses of UVC light (265 nm, 1.93 mW/cm2) for 5, 10, 15, 30, or 60 min (exposure groups) or remained unexposed for the same durations (control groups), with a sample size of 6 per group. In parallel, human corneal tissue was exposed to UVC for 1 or 5 min and processed identically. Following exposure, all tissues were frozen, dissected, and analysed using immunohistochemistry to detect cyclobutane pyrimidine dimers (CPDs) as markers of DNA damage. CPD distribution, depth, and density were subsequently evaluated. Results: CPDs were localised predominantly in the superficial corneal epithelial layers, irrespective of the UVC dose. The mean ± SD thickness of the corneal epithelium in the UVC-exposed groups was 38.9 ± 18.9 µm, and the average depth of CPD formation was 13.3 ± 8.43 µm. The proportions of cells affected by CPDs within the corneal epithelium (mean ± SD) were 47.8 ± 25.6%, 58.5 ± 16.2%, 39.9 ± 26.4%, 41.3 ± 27.3%, and 38.9 ± 28.3% for exposure durations of 5, 10, 15, 30, and 60 min, respectively (p > 0.05). Human cornea showed similarly limited penetration, with no difference in CPD proportions between the 1 and 5 min UVC exposures (p = 0.70). Conclusions: UVC-induced DNA damage in both species was confined to the superficial cellular layers of the cornea, with no detectable damage observed in deeper tissues, including those where limbal stem cells reside, even after supratherapeutic doses of up to one hour of exposure.
- Open Access
- 24 March 2026
- Published by Elsevier in Contact Lens and Anterior Eye
- Vol. 49 (3) , 102650
Validity and reliability of the Nepali version of the ocular surface disease index questionnaire for assessing quality of life in dry eye patients
- 24 March 2026
- Published by Elsevier in Contact Lens and Anterior Eye
- Vol. 49 (3) , 102650
Open AccessValidity and reliability of the Nepali version of the ocular surface disease index questionnaire for assessing quality of life in dry eye patients
- Open Access
- 21 May 2025
- Published by Elsevier in Contact Lens and Anterior Eye
- Vol. 48 (5) , 102437
Comparison of antimicrobial efficacy and safety of pulsed versus continuous wave UVC
- 21 May 2025
- Published by Elsevier in Contact Lens and Anterior Eye
- Vol. 48 (5) , 102437
Open AccessComparison of antimicrobial efficacy and safety of pulsed versus continuous wave UVC
- Open Access
- 1 April 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (4) , 361
Therapeutic Efficacy of Ultraviolet C Light on Fungal Keratitis—In Vitro and Ex Vivo Studies
Objective: Fungal corneal infections are challenging to treat due to delayed diagnostic procedures, bacterial co-infections, and limited antifungal efficacy. This study investigates the therapeutic potential of ultraviolet C (UVC) light alone and combined with antifungal drugs. Methods: A subsurface infection model was developed in semi-solid agar droplets, with Candida albicans cells or Aspergillus brasiliensis spores inoculated into 0.75% w/v yeast peptone dextrose (YPD) agar in a 96-well microplate (5 µL per well). Two treatment groups were tested: (1) UVC exposure (265 nm, 1.93 mW/cm2) for durations of 0 s, 5 s, 10 s, 15 s, 30 s, 60 s, or 120 s, and (2) UVC combined with antifungal drugs (Amphotericin B and Natamycin) at their minimum inhibitory concentrations (MICs), determined in YPD broth. After treatment, agar droplets were homogenized, diluted, and plated for microbial enumeration. The most effective UVC doses were further tested in an ex vivo C. albicans porcine keratitis model, where the corneal epithelium was debrided, infected with C. albicans, and exposed to UVC. Corneas were then homogenized and plated to evaluate treatment efficacy. Results: UVC exposure of ≥15 s inhibited C. albicans, and ≥10 s inhibited A. brasiliensis (all p < 0.05). The broth MICs were 0.1875 µg/mL for Amphotericin B against C. albicans, 6.25 µg/mL against A. brasiliensis, and 0.78125 µg/mL for Natamycin against C. albicans, 7.8125 µg/mL against A. brasiliensis. The broth MIC did not eradicate fungi in the subsurface model. Combined treatments enhanced inhibition (all p < 0.05), with 30 s UVC + amphotericin B for C. albicans (p = 0.0218) and 30 s UVC + natamycin for A. brasiliensis (p = 0.0017). Ex vivo, 15 s and 30 s UVC inhibited growth (p = 0.0476), but no differences were seen between groups (all p > 0.05). Conclusion: UVC demonstrated strong antifungal efficacy, with supplementary benefits from combining UVC with low doses of antifungal drugs.
- 1 April 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (4) , 361
Open AccessTherapeutic Efficacy of Ultraviolet C Light on Fungal Keratitis—In Vitro and Ex Vivo Studies
Objective: Fungal corneal infections are challenging to treat due to delayed diagnostic procedures, bacterial co-infections, and limited antifungal efficacy. This study investigates the therapeutic potential of ultraviolet C (UVC) light alone and combined with antifungal drugs. Methods: A subsurface infection model was developed in semi-solid agar droplets, with Candida albicans cells or Aspergillus brasiliensis spores inoculated into 0.75% w/v yeast peptone dextrose (YPD) agar in a 96-well microplate (5 µL per well). Two treatment groups were tested: (1) UVC exposure (265 nm, 1.93 mW/cm2) for durations of 0 s, 5 s, 10 s, 15 s, 30 s, 60 s, or 120 s, and (2) UVC combined with antifungal drugs (Amphotericin B and Natamycin) at their minimum inhibitory concentrations (MICs), determined in YPD broth. After treatment, agar droplets were homogenized, diluted, and plated for microbial enumeration. The most effective UVC doses were further tested in an ex vivo C. albicans porcine keratitis model, where the corneal epithelium was debrided, infected with C. albicans, and exposed to UVC. Corneas were then homogenized and plated to evaluate treatment efficacy. Results: UVC exposure of ≥15 s inhibited C. albicans, and ≥10 s inhibited A. brasiliensis (all p < 0.05). The broth MICs were 0.1875 µg/mL for Amphotericin B against C. albicans, 6.25 µg/mL against A. brasiliensis, and 0.78125 µg/mL for Natamycin against C. albicans, 7.8125 µg/mL against A. brasiliensis. The broth MIC did not eradicate fungi in the subsurface model. Combined treatments enhanced inhibition (all p < 0.05), with 30 s UVC + amphotericin B for C. albicans (p = 0.0218) and 30 s UVC + natamycin for A. brasiliensis (p = 0.0017). Ex vivo, 15 s and 30 s UVC inhibited growth (p = 0.0476), but no differences were seen between groups (all p > 0.05). Conclusion: UVC demonstrated strong antifungal efficacy, with supplementary benefits from combining UVC with low doses of antifungal drugs.
- Open Access
- 5 January 2025
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 263, 113091
In vitro anti-biofilm efficacy of therapeutic low dose 265 nm UVC
- 5 January 2025
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 263, 113091
Open AccessIn vitro anti-biofilm efficacy of therapeutic low dose 265 nm UVC
- 1 May 2024
- Published by Wiley in Optometry and Vision Science
- Vol. 101 (5) , 272-275
Central corneal thickness in new cases of dry eyes: A case‐control study
Significance: Loss of homeostasis and chronic inflammation result in ocular surface damage in dry eyes, which is also associated with corneal thinning in established cases. Yet, the correlation between corneal thickness and new cases of dry eyes remains inadequately supported by evidence. Purpose: This study aimed to compare the central corneal thickness of new cases of dry eyes to that of age‐ and gender‐matched controls. Methods: A total of 45 dry eye patients were compared with 61 age‐ and gender‐matched non–dry eye individuals. The Ocular Surface Disease Index (OSDI) questionnaire was used to evaluate symptoms, and the central corneal thickness was measured with a Nidek CEM‐530 specular microscope. Patients were grouped based on disease severity (OSDI scores), and the clinical findings were compared between groups for slit‐lamp examinations, Schirmer's I test, and tear film breakup time. Results: The median age of patients was 25.0 (interquartile range [IQR], 20.0 to 32.0) and 27.0 (IQR, 20.0 to 32.0) years in the control and dry eye groups, respectively (p=0.63). The median (IQR) values of the OSDI scores, tear film breakup time scores, and Schirmer's test measurements in the control groups were 10.4 (8.3 to 10.4), 12.0 (11.0 to 14.0) seconds, and 16.0 (13.5 to 19.5) mm, respectively, which differed from the dry eye groups (p<0.0001). These values in the dry eye group were 29.1 (25.0 to 39.5), 4.0 (3.0 to 8.0) seconds, and 8.0 (3.5 to 11.0) mm, respectively. Patients with dry eyes had lower central corneal thickness than controls (p<0.01). The mean ± standard deviation central corneal thicknesses in patients with dry eyes and the control group were 520.3 ± 26.8 and 545.3 ± 18.8 μm, respectively. Conclusions: The central corneal thickness in dry eyes was significantly reduced compared with the control group. These findings may be useful in monitoring and managing dry eyes and should be considered in intraocular pressure measurements and refractive surgical procedures.
- 1 May 2024
- Published by Wiley in Optometry and Vision Science
- Vol. 101 (5) , 272-275
Central corneal thickness in new cases of dry eyes: A case‐control study
Significance: Loss of homeostasis and chronic inflammation result in ocular surface damage in dry eyes, which is also associated with corneal thinning in established cases. Yet, the correlation between corneal thickness and new cases of dry eyes remains inadequately supported by evidence. Purpose: This study aimed to compare the central corneal thickness of new cases of dry eyes to that of age‐ and gender‐matched controls. Methods: A total of 45 dry eye patients were compared with 61 age‐ and gender‐matched non–dry eye individuals. The Ocular Surface Disease Index (OSDI) questionnaire was used to evaluate symptoms, and the central corneal thickness was measured with a Nidek CEM‐530 specular microscope. Patients were grouped based on disease severity (OSDI scores), and the clinical findings were compared between groups for slit‐lamp examinations, Schirmer's I test, and tear film breakup time. Results: The median age of patients was 25.0 (interquartile range [IQR], 20.0 to 32.0) and 27.0 (IQR, 20.0 to 32.0) years in the control and dry eye groups, respectively (p=0.63). The median (IQR) values of the OSDI scores, tear film breakup time scores, and Schirmer's test measurements in the control groups were 10.4 (8.3 to 10.4), 12.0 (11.0 to 14.0) seconds, and 16.0 (13.5 to 19.5) mm, respectively, which differed from the dry eye groups (p<0.0001). These values in the dry eye group were 29.1 (25.0 to 39.5), 4.0 (3.0 to 8.0) seconds, and 8.0 (3.5 to 11.0) mm, respectively. Patients with dry eyes had lower central corneal thickness than controls (p<0.01). The mean ± standard deviation central corneal thicknesses in patients with dry eyes and the control group were 520.3 ± 26.8 and 545.3 ± 18.8 μm, respectively. Conclusions: The central corneal thickness in dry eyes was significantly reduced compared with the control group. These findings may be useful in monitoring and managing dry eyes and should be considered in intraocular pressure measurements and refractive surgical procedures.
- Open Access
- 12 September 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (9) , 1437
Antimicrobial Resistance: Is There a ‘Light’ at the End of the Tunnel?
In recent years, with the increases in microorganisms that express a multitude of antimicrobial resistance (AMR) mechanisms, the threat of antimicrobial resistance in the global population has reached critical levels. The introduction of the COVID-19 pandemic has further contributed to the influx of infections caused by multidrug-resistant organisms (MDROs), which has placed significant pressure on healthcare systems. For over a century, the potential for light-based approaches targeted at combatting both cancer and infectious diseases has been proposed. They offer effective killing of microbial pathogens, regardless of AMR status, and have not typically been associated with high propensities of resistance development. To that end, the goal of this review is to describe the different mechanisms that drive AMR, including intrinsic, phenotypic, and acquired resistance mechanisms. Additionally, the different light-based approaches, including antimicrobial photodynamic therapy (aPDT), antimicrobial blue light (aBL), and ultraviolet (UV) light, will be discussed as potential alternatives or adjunct therapies with conventional antimicrobials. Lastly, we will evaluate the feasibility and requirements associated with integration of light-based approaches into the clinical pipeline.
- 12 September 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (9) , 1437
Open AccessAntimicrobial Resistance: Is There a ‘Light’ at the End of the Tunnel?
In recent years, with the increases in microorganisms that express a multitude of antimicrobial resistance (AMR) mechanisms, the threat of antimicrobial resistance in the global population has reached critical levels. The introduction of the COVID-19 pandemic has further contributed to the influx of infections caused by multidrug-resistant organisms (MDROs), which has placed significant pressure on healthcare systems. For over a century, the potential for light-based approaches targeted at combatting both cancer and infectious diseases has been proposed. They offer effective killing of microbial pathogens, regardless of AMR status, and have not typically been associated with high propensities of resistance development. To that end, the goal of this review is to describe the different mechanisms that drive AMR, including intrinsic, phenotypic, and acquired resistance mechanisms. Additionally, the different light-based approaches, including antimicrobial photodynamic therapy (aPDT), antimicrobial blue light (aBL), and ultraviolet (UV) light, will be discussed as potential alternatives or adjunct therapies with conventional antimicrobials. Lastly, we will evaluate the feasibility and requirements associated with integration of light-based approaches into the clinical pipeline.
- Open Access
- 18 August 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (8) , 1334
Managing Corneal Infections: Out with the old, in with the new?
There have been multiple reports of eye infections caused by antibiotic-resistant bacteria, with increasing evidence of ineffective treatment outcomes from existing therapies. With respect to corneal infections, the most commonly used antibiotics (fluoroquinolones, aminoglycosides, and cephalosporines) are demonstrating reduced efficacy against bacterial keratitis isolates. While traditional methods are losing efficacy, several novel technologies are under investigation, including light-based anti-infective technology with or without chemical substrates, phage therapy, and probiotics. Many of these methods show non-selective antimicrobial activity with potential development as broad-spectrum antimicrobial agents. Multiple preclinical studies and a limited number of clinical case studies have confirmed the efficacy of some of these novel methods. However, given the rapid evolution of corneal infections, their treatment requires rapid institution to limit the impact on vision and prevent complications such as scarring and corneal perforation. Given their rapid effects on microbial viability, light-based technologies seem particularly promising in this regard.
- 18 August 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (8) , 1334
Open AccessManaging Corneal Infections: Out with the old, in with the new?
There have been multiple reports of eye infections caused by antibiotic-resistant bacteria, with increasing evidence of ineffective treatment outcomes from existing therapies. With respect to corneal infections, the most commonly used antibiotics (fluoroquinolones, aminoglycosides, and cephalosporines) are demonstrating reduced efficacy against bacterial keratitis isolates. While traditional methods are losing efficacy, several novel technologies are under investigation, including light-based anti-infective technology with or without chemical substrates, phage therapy, and probiotics. Many of these methods show non-selective antimicrobial activity with potential development as broad-spectrum antimicrobial agents. Multiple preclinical studies and a limited number of clinical case studies have confirmed the efficacy of some of these novel methods. However, given the rapid evolution of corneal infections, their treatment requires rapid institution to limit the impact on vision and prevent complications such as scarring and corneal perforation. Given their rapid effects on microbial viability, light-based technologies seem particularly promising in this regard.
- 26 June 2023
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 199, 114971
Erratum to “Can microorganisms develop resistance against light based anti-infective agents?” [Adv. Drug Delivery Rev. 175 (2021) 113822]
- 26 June 2023
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 199, 114971
Erratum to “Can microorganisms develop resistance against light based anti-infective agents?” [Adv. Drug Delivery Rev. 175 (2021) 113822]
- 1 August 2021
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 175, 113822
Can microorganisms develop resistance against light based anti-infective agents?
- 1 August 2021
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 175, 113822
Can microorganisms develop resistance against light based anti-infective agents?